Bangladesh, Oct. 16 -- Beacon Pharmaceuticals reported a strong financial performance for FY26, with significant growth in earnings, net asset value and operating cash flow.Track Biotech

The company secured a profit of Tk 1.94 billion in FY26, up 105 per cent from the previous year. It said the surge in earnings was fuelled by a 30.96 per cent increase in sales in FY26 compared with the previous year, according to the price-sensitive information disclosed on Thursday following a board meeting.

The company's earnings per share (EPS) stood at Tk 8.41 in FY26, up from Tk 4.10 in the previous year.

Beacon Pharma's net asset value (NAV) per share increased 24.14 per cent year-on-year to Tk 35.83 in FY26. This rise in asset value indicates ...